{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=41",
    "query": {
      "intervention": "Peripheral Blood",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 20701,
    "total_pages": 2071,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Peripheral+Blood&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-16T14:18:31.412Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00244361",
      "title": "Effectiveness of Rituximab in Pediatric OMS Patients.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Opsoclonus-myoclonus Syndrome",
        "Opsoclonus",
        "Myoclonus",
        "Ataxia"
      ],
      "interventions": [
        {
          "name": "rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Pediatric Neuroinflammation Organization, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "6 Months to 19 Years"
      },
      "enrollment_count": 25,
      "start_date": "2005-06",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2011-05-10",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "Springfield, Illinois",
      "locations": [
        {
          "city": "Springfield",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00244361"
    },
    {
      "nct_id": "NCT05587673",
      "title": "High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Inflammatory Bowel Diseases",
        "Crohn Disease",
        "Ulcerative Colitis",
        "Indeterminate Colitis"
      ],
      "interventions": [
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "4 Years to 25 Years"
      },
      "enrollment_count": 3,
      "start_date": "2022-10-06",
      "completion_date": "2024-10-11",
      "has_results": false,
      "last_update_posted_date": "2024-11-26",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05587673"
    },
    {
      "nct_id": "NCT00074269",
      "title": "Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "graft-versus-tumor induction therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 5,
      "start_date": "2003-07",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074269"
    },
    {
      "nct_id": "NCT00696241",
      "title": "Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Azilsartan medoxomil and olmesartan",
          "type": "DRUG"
        },
        {
          "name": "Olmesartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1275,
      "start_date": "2007-06",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2011-07-29",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 80,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 77 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00696241"
    },
    {
      "nct_id": "NCT02200562",
      "title": "Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage III or IV Melanoma"
      ],
      "interventions": [
        {
          "name": "ipilimumab and dabrafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2014-12",
      "completion_date": "2017-01-20",
      "has_results": false,
      "last_update_posted_date": "2017-03-01",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02200562"
    },
    {
      "nct_id": "NCT01960946",
      "title": "Galectin-3 Blockade in Patients With High Blood Pressure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Modified Citrus Pectin (MCP) vs placebo",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 59,
      "start_date": "2013-10",
      "completion_date": "2018-08-30",
      "has_results": false,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01960946"
    },
    {
      "nct_id": "NCT04905446",
      "title": "Measurement of NAD+ Synthesis in Human Skeletal Muscle",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Skeletal Muscle"
      ],
      "interventions": [
        {
          "name": "Deuterated nicotinamide (D4-NAM) IV infusion",
          "type": "OTHER"
        },
        {
          "name": "Skeletal muscle biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Skin tissue biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "AdventHealth Translational Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "21 Years to 40 Years · Male only"
      },
      "enrollment_count": 15,
      "start_date": "2021-09-10",
      "completion_date": "2024-12-20",
      "has_results": false,
      "last_update_posted_date": "2025-03-13",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04905446"
    },
    {
      "nct_id": "NCT05670288",
      "title": "Impact of Gut Microbiome on Metabolic and Bowel Function During the First Year After Spinal Cord Injury",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Spinal Cord Injuries",
        "Gut Microbiome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 35,
      "start_date": "2023-10-15",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05670288"
    },
    {
      "nct_id": "NCT00272961",
      "title": "A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Resistant Hypertension"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TBC3711",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2006-01",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2013-03-05",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00272961"
    },
    {
      "nct_id": "NCT00513786",
      "title": "Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "David O'Malley",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 38,
      "start_date": "2007-08-01",
      "completion_date": "2017-01-03",
      "has_results": true,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-11-16T14:18:31.412Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00513786"
    }
  ]
}